Johnson & Johnson recently rolled out a TV ad that takes aim at a major disparity in dermatology: the fact that people of color with psoriasis are 70% less likely to be prescribed a biologic than ...

Last year, AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading the pair of immunology meds to take the full-year title for the ...

Johnson & Johnson is changing up the look and tone for psoriasis med Tremfya's advertising to reflect patients' real-life experiences. The more somber, darkly lit TV ads vividly depict the shackles of ...

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. With ...